CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer due to its lack of treatment options. Patients with TNBC frequently develop resistance to chemotherapy. As epigenetic-based antineoplastic drugs, histone deacetylase inhibitors (HDACis) have achieved particular efficacy...
Main Authors: | Xin-le Han, Jun Du, Ya-dan Zheng, Jia-jing Dai, Su-wen Lin, Bing-yue Zhang, Fu-bo Zhong, Zhe-guang Lin, Shu-qi Jiang, Wei Wei, Zheng-yu Fang |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2021-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2021/5089371 |
Similar Items
-
Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
by: João Lobo, et al.
Published: (2020-10-01) -
Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas
by: Allen PB, et al.
Published: (2018-12-01) -
CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer
by: Yuan-ke Liang, et al.
Published: (2021-08-01) -
Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
by: Bodiford A, et al.
Published: (2014-10-01) -
Epigenetic and Transcriptional Response to HDAC Inhibition in Triple Negative Breast Cancer Cells
by: Walheim, Danielle Marie
Published: (2016)